Company news
Spyre Therapeutics, Inc. (NASDAQ:SYRE) news
Spyre Therapeutics, Inc. news releases on 6ix. Latest, Jan 25, 2022: Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1…
Press releases — page 3
Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency
January 24, 2022
Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
January 4, 2022
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
December 5, 2021
Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency
December 4, 2021
Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors
November 15, 2021
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 3, 2021
Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics
November 3, 2021
Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
August 31, 2021
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 4, 2021
Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel
July 14, 2021
Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease
July 13, 2021
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
July 7, 2021
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria
June 23, 2021
Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
June 21, 2021
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
May 9, 2021
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency
May 5, 2021
Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency
May 2, 2021
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
March 31, 2021
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East
March 21, 2021
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
March 17, 2021
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
February 23, 2021
Aeglea BioTherapeutics Announces Transition of Chief Financial Officer
February 2, 2021
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 3, 2021
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
December 16, 2020
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
November 30, 2020
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
November 23, 2020
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
November 16, 2020
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 4, 2020
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
October 25, 2020
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
October 4, 2020
Aeglea BioTherapeutics to Participate in September Investment Conferences
September 1, 2020
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
August 17, 2020
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
August 9, 2020
Aeglea BioTherapeutics to Present at BIO Digital 2020
May 31, 2020
Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020
May 27, 2020
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 25, 2020
Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 18, 2020
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
May 6, 2020
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 29, 2020
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
April 27, 2020
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
April 7, 2020
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
February 23, 2020
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
January 12, 2020
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
January 5, 2020
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
November 25, 2019
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
November 5, 2019
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
November 3, 2019